Table 2. Model Parameter Values: Screening and Treatment Response Characteristics.

	Base	Min	Max	Source
Screening Test Characteristics
FibroTest (FibroSure)
Probability for patients with F0–F1				[6], [8], [19], [20]
Test + (>0.58)	0.13	0.06	0.15
Test − (<0.31), specificity at 0.31	0.68	0.57	0.72
Probability for patients with F2–F4
Test + (>0.58), sensitivity at 0.58	0.56	0.35	0.59
Test − (<0.31)	0.16	0.12	0.29
Liver biopsy screening frequency (year)	3	3	5	[47]
Treatment Response Probability
Standard treatment (peginterferon and ribavirin)
Probability(EVR at 12 week), genotype 1	0.71	0.66	0.76	[28]
Probability(SVR | EVR), genotype 1	0.63	0.57	0.69	[28]
Probability(SVR), genotype 2 and 3	0.80	0.60	1.00	[1], [10], [28], [34]
Triple therapy (peginterferon+ribavirin+telaprevir), genotype 1a				[9]
Probability(virologic failure at 12 week)	0.03
Probability(eRVR+, 24 week treatment | non-failure at 12 week)	0.60
Probability(eRVR−, 48 week treatment | non-failure at 12 week)	0.35
Probability(SVR|eRVR+, 24 week treatment)	0.89
Probability(SVR|eRVR−, 48 week treatment)	0.67
Noncompliance	0	0	0.63	[29]

^aThe effectiveness listed for triple therapy are for patients with fibrosis stage F0 to F2; for patients with fibrosis stage F3 and F4, SVR is reduced by 20%.